324 related articles for article (PubMed ID: 25732247)
21. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
[TBL] [Abstract][Full Text] [Related]
22. Discontinuing chemoimmunotherapy in childhood acute lymphoblastic leukemia.
Komada Y; Azuma E; Yamamoto H; Tanaka S; Shimizu K; Kamiya H; Sakurai M; Izawa T
Biomed Pharmacother; 1988; 42(9):597-603. PubMed ID: 3240364
[TBL] [Abstract][Full Text] [Related]
23. Direct CNS administration of rituximab and epratuzumab in a pediatric patient with relapsed refractory CNS B-cell acute lymphoblastic leukemia.
McClane J; Chawla A; Welch JJG
Pediatr Blood Cancer; 2022 Jun; 69(6):e29664. PubMed ID: 35293685
[TBL] [Abstract][Full Text] [Related]
24. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
Jabbour E; Sasaki K; Ravandi F; Huang X; Short NJ; Khouri M; Kebriaei P; Burger J; Khoury J; Jorgensen J; Jain N; Konopleva M; Garcia-Manero G; Kadia T; Cortes J; Jacob J; Montalbano K; Garris R; O'Brien S; Kantarjian HM
Cancer; 2018 Oct; 124(20):4044-4055. PubMed ID: 30307611
[TBL] [Abstract][Full Text] [Related]
25. Bone marrow transplantation versus chemotherapy for maintenance of second remission of childhood acute lymphoblastic leukemia: a study of the Children's Cancer Group (CCG-1884).
Feig SA; Harris RE; Sather HN
Med Pediatr Oncol; 1997 Dec; 29(6):534-40. PubMed ID: 9324340
[TBL] [Abstract][Full Text] [Related]
26. Long-term results of Taiwan Pediatric Oncology Group studies 1997 and 2002 for childhood acute lymphoblastic leukemia.
Liang DC; Yang CP; Lin DT; Hung IJ; Lin KH; Chen JS; Hsiao CC; Chang TT; Peng CT; Lin MT; Chang TK; Jaing TH; Liu HC; Wang LY; Yeh TC; Jou ST; Lu MY; Cheng CN; Sheen JM; Chiou SS; Wu KH; Hung GY; Chen RL; Chen SH; Cheng SN; Chang YH; Chen BW; Ho WL; Wang JL; Lin ST; Hsieh YL; Wang SC; Chang HH; Yang YL; Huang FL; Chang CY; Chang WH; Lin KS
Leukemia; 2010 Feb; 24(2):397-405. PubMed ID: 20016538
[TBL] [Abstract][Full Text] [Related]
27. Salvage therapy for children with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.
Kodama Y; Manabe A; Kawasaki H; Kato I; Kato K; Sato A; Matsumoto K; Kato M; Hiramatsu H; Sano H; Kaneko T; Oda M; Saito AM; Adachi S; Horibe K; Mizutani S; Ishii E; Shimada H
Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28084041
[TBL] [Abstract][Full Text] [Related]
28. Long-term results of treatment of childhood acute lymphoblastic leukemia in the Czech Republic.
Stary J; Jabali Y; Trka J; Hrusak O; Gajdos P; Hrstkova H; Sterba J; Blazek B; Hak J; Prochazkova D; Cerna Z; Smisek P; Sedlacek P; Vavra V; Mihal V; Hrodek O;
Leukemia; 2010 Feb; 24(2):425-8. PubMed ID: 20016535
[No Abstract] [Full Text] [Related]
29. Long-term results of the Israeli National Studies in childhood acute lymphoblastic leukemia: INS 84, 89 and 98.
Stark B; Nirel R; Avrahami G; Abramov A; Attias D; Ballin A; Bielorai B; Burstein Y; Gavriel H; Elhasid R; Kapelushnik J; Sthoeger D; Toren A; Wientraub M; Yaniv I; Izraeli S
Leukemia; 2010 Feb; 24(2):419-24. PubMed ID: 20016534
[No Abstract] [Full Text] [Related]
30. Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): a report from the Children's Oncology Group.
Cooper TM; Razzouk BI; Gerbing R; Alonzo TA; Adlard K; Raetz E; Gamis AS; Perentesis J; Whitlock JA
Pediatr Blood Cancer; 2013 Jul; 60(7):1141-7. PubMed ID: 23335239
[TBL] [Abstract][Full Text] [Related]
31. Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study.
Chevallier P; Huguet F; Raffoux E; Etienne A; Leguay T; Isnard F; Robillard N; Guillaume T; Delaunay J; Charbonnier A; Pigneux A; Peterlin P; Bené MC; Wegener WA; Goldenberg DM; Dombret H
Haematologica; 2015 Apr; 100(4):e128-31. PubMed ID: 25552705
[No Abstract] [Full Text] [Related]
32. (90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study.
Chevallier P; Eugene T; Robillard N; Isnard F; Nicolini F; Escoffre-Barbe M; Huguet F; Hunault M; Marcais A; Gaschet J; Cherel M; Guillaume T; Delaunay J; Peterlin P; Eveillard M; Thomas X; Ifrah N; Lapusan S; Bodet-Milin C; Barbet J; Faivre-Chauvet A; Ferrer L; Bene MC; Le Houerou C; Goldenberg DM; Wegener WA; Kraeber-Bodéré F
Lancet Haematol; 2015 Mar; 2(3):e108-17. PubMed ID: 26687796
[TBL] [Abstract][Full Text] [Related]
33. Palbociclib in combination with chemotherapy in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia and lymphoma: A Children's Oncology Group study (AINV18P1).
Raetz EA; Teachey DT; Minard C; Liu X; Norris RE; Denic KZ; Reid J; Evensen NA; Gore L; Fox E; Loh ML; Weigel BJ; Carroll WL
Pediatr Blood Cancer; 2023 Nov; 70(11):e30609. PubMed ID: 37553297
[TBL] [Abstract][Full Text] [Related]
34. Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial.
Jabbour E; Ravandi F; Kebriaei P; Huang X; Short NJ; Thomas D; Sasaki K; Rytting M; Jain N; Konopleva M; Garcia-Manero G; Champlin R; Marin D; Kadia T; Cortes J; Estrov Z; Takahashi K; Patel Y; Khouri MR; Jacob J; Garris R; O'Brien S; Kantarjian H
JAMA Oncol; 2018 Feb; 4(2):230-234. PubMed ID: 28859185
[TBL] [Abstract][Full Text] [Related]
35. Allogeneic bone marrow transplantation for a subset of children with acute lymphoblastic leukemia in third remission: a conceivable alternative?
Borgmann A; Baumgarten E; Schmid H; Dopfer R; Ebell W; Göbel U; Niethammer D; Gadner H; Henze G
Bone Marrow Transplant; 1997 Dec; 20(11):939-44. PubMed ID: 9422472
[TBL] [Abstract][Full Text] [Related]
36. Results of treatment of lymphoblastic lymphoma at the children cancer hospital Egypt - A single center experience.
Rahman Sayed HA; Sedky M; Hamoda A; Kinaaie NE; Wakeel ME; Hesham D
J Egypt Natl Canc Inst; 2016 Sep; 28(3):175-81. PubMed ID: 27339800
[TBL] [Abstract][Full Text] [Related]
37. Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma.
Witzig TE; Tomblyn MB; Misleh JG; Kio EA; Sharkey RM; Wegener WA; Goldenberg DM
Haematologica; 2014 Nov; 99(11):1738-45. PubMed ID: 25150258
[TBL] [Abstract][Full Text] [Related]
38. Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia.
Kato K; Yoshida N; Matsumoto K; Matsuyama T
Pediatr Blood Cancer; 2014 Apr; 61(4):712-6. PubMed ID: 24376191
[TBL] [Abstract][Full Text] [Related]
39. How I treat relapsed childhood acute lymphoblastic leukemia.
Locatelli F; Schrappe M; Bernardo ME; Rutella S
Blood; 2012 Oct; 120(14):2807-16. PubMed ID: 22896001
[TBL] [Abstract][Full Text] [Related]
40. Early responses to chemotherapy of normal and malignant hematologic cells are prognostic in children with acute lymphoblastic leukemia.
Laughton SJ; Ashton LJ; Kwan E; Norris MD; Haber M; Marshall GM
J Clin Oncol; 2005 Apr; 23(10):2264-71. PubMed ID: 15800317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]